The year in cardiology 2015: Heart failure

European Heart Journal

Volumn 37, Issue 5, 2016, Pages 437-441

  Komajda, Michel ^a   Ruschitzka, Frank ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BENZNIDAZOLE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ANTITRYPANOSOMAL AGENT; NITROIMIDAZOLE DERIVATIVE;

ADAPTIVE SERVO VENTILATION; ALCOHOL CONSUMPTION; ANGIONEUROTIC EDEMA; ARTIFICIAL VENTILATION; CENTRAL SLEEP APNEA SYNDROME; CHAGAS DISEASE; DRUG TREATMENT FAILURE; GENE THERAPY; HEART EJECTION FRACTION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; TREATMENT FAILURE; ADVERSE EFFECTS; CHAGAS CARDIOMYOPATHY; CHEMICALLY INDUCED; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; DRINKING BEHAVIOR; PROCEDURES; SLEEP APNEA, CENTRAL;

ALCOHOL DRINKING; ANGIOEDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHAGAS CARDIOMYOPATHY; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; GENETIC THERAPY; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; NITROIMIDAZOLES; RESPIRATION, ARTIFICIAL; RISK FACTORS; SLEEP APNEA, CENTRAL; TRYPANOCIDAL AGENTS;

EID: 84960091111     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv720     Document Type: Review

References (15)

1. Cowie MR, Woehrle H, Wegscheider K, Angermann C, D'Ortho MP, Erdmann E, Levy P, Simonds A, Somers VK, Zannad F, Somers VK. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med 2015. doi: 10.1056/ NEJMoa1506459.
2. Scirica BM, Bhatt DL, Braunwald E, Steg G, Davison J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mozenson O, McGuire DK, Ray KK, Leiter LA, Raz I. for the SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369: 1317-1326.
3. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F. EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369: 1327-1335.
4. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR. TECOS Study Group. Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015; 373: 232-242.
5. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, JohansenOE,Woerle HJ, Broedl UC, Inzucchi SE. EMPA-REGOUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015. doi: 10.1056/NEJMoal501720 [Epub ahead of print].
6. Sakata Y, Shiba N, Takahashi J, Miyata S, Nochioka K, Miura M, Takada T, Saga C, Shinozaki T, Sugi M, Nakagawa M, Sekiguchi N, Komaru T, Kato A, Fukuchi M, Nozaki E, Hiramoto T, Inoue K, Goto T, Ohe M, Tamaki K, Ibayashi S, Ishide N, Maruyama Y, Tsuji I, Shimokawa H. SUPPORT Trial Investigators. SUPPORT Trial Investigators. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Eur Heart J. 2015; 36: 915-923.
7. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E. RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013; 309: 1268-1277.
8. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011; 124: 164-174.
9. Hoendermis ES, Liu LC, Hummel YM, van der Meer P, de Boer RA, Berger RM, van Veldhuisen DJ, Voors AA. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J. 2015; 36: 2565-2573.
10. Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CSP, Maggioni AP, Ponikowski P, Shah SJ, Solomon SD, Kraigher-Krainer E, Samano ET, Mü ller K, Roessig L, Pieske B. for the SOCRATES-REDUCED Investigators and Coordinators. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: The SOCRATES-REDUCED randomized trial. JAMA. 2015; 314: 2251-2262.
11. Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, LeWinter MM, Joseph SM, Shah SJ, Semigran MJ, Felker GM, Cole RT, Reeves GR, Tedford RJ, Tang WH, McNulty SE, Velazquez EJ, Shah MR, Braunwald E. NHLBI Heart Failure Clinical Research Network. Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med 2015 [Epub ahead of print].
12. Baş M, Greve J, Stelter K, Havel M, Strassen U, Rotter N, Veit J, Schossow B, Hapfelmeier A, Kehl V, Kojda G, Hoffmann TK A randomized trial of icatibant in ACE-inhibitor-induced angioedema. N Engl J Med. 2015; 372: 418-425.
13. Gonc'alves A, Claggett B, Jhund PS, Rosamond W, Deswal A, Aguilar D, Shah AM, Cheng S, Solomon SD. Alcohol consumption and risk of heart failure: The Atherosclerosis Risk in Communities Study. Eur Heart J. 2015; 36: 939-945.
14. Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Desai AS, Barnard D, Bouchard A, Jaski B, Lyon AR, Pogoda JM, Rudy JJ, Zsebo KM. Calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b (CUPID 2): a randomised, multinational, double-blind, placebo-controlled trial. The Lancet 2016. (in press
15. Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A Jr, Rosas F, Villena E, Quiroz R, Bonilla R, Britto C, Guhl F, Velazquez E, Bonilla L, Meeks B, Rao-Melacini P, Pogue J, Mattos A, Lazdins J, Rassi A, Connolly SJ, Yusuf S. BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. N Engl J Med 2015 [Epub ahead of print].